浙富控股(002266.SZ):中標1.35億元第001標段四川公司阿水公司綽斯甲水電站水輪發電機組及其附屬設備
格隆匯1月5日丨浙富控股(002266.SZ)公佈,公司近日收到中國神華國際工程有限公司的《中標通知書》,通知確定本公司為第001標段四川公司阿水公司綽斯甲水電站水輪發電機組及其附屬設備採購項目的中標單位。雙方將盡快簽署正式採購合同。中標總金額為1.35億元。
本次中標總金額約佔公司2020年度營業收入的1.62%,按照21個月交貨期安排,平均佔2020年度營業收入的0.92%,公司將按照交貨進度生產部件並確認銷售收入,預計將增加公司2022年—2024年的銷售收入和淨利潤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.